Urogen Pharma up on higher Q1 cancer drug sales

UroGen Pharma

11/05/2023 18:50

** U.S.-listed shares of Israeli drug developer Urogen
Pharma  URGN.O  rise 2.3% to $11.77
    ** Reports Q1 adj loss of $1.30 vs analysts' est of $1.33 -
Refinitiv data 
    ** Rev rose 26.7% to $17.19 mln from a year ago, analysts
expected $17.18 mln; rise in Q1 rev driven by higher sales for
its cancer drug, Jelmyto
    ** Jelmyto quarterly sales were $17.2 mln, compared to $13.6
mln a year earlier
    ** Reiterates anticipated FY 2023 net product revenues from
Jelmyto to be in $76 mln-$86 mln range 
    ** Analysts expect Jelmyto rev to be $97.43 mln for FY 2023
    ** YTD, stock up 32.6%, including session's gain 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))